TheEdgeResearch
Home / Stocks / GLABF

Gemina Laboratories Ltd. (GLABF)

OTC Healthcare Biotechnology
$0.05 ▲ +0.00%
Market Cap
$3.8M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.07
52-Wk Range
0.0375-0.3439
CEO
Robert Crandall Greene
Country
CA
Currency
USD

Gemina Laboratories Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Burnaby, BC, CA. The stock last traded at $0.05, up 0.00% on the session, giving a market capitalisation of $3.8M. On trailing twelve-month figures it carries a trailing P/E of -6.12, a net margin of 0.0%. Its beta of -0.07 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-6.12
Price / Sales
0.00
Price / Book
-0.89
EV / EBITDA
-6.51
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
-0.05
Current ratio
0.01
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
6
IPO date
2022-03-29
Headquarters
Burnaby, BC, CA
About Gemina Laboratories Ltd.

Gemina Laboratories Ltd. is a Canadian biotechnology company dedicated to the research, development, and commercialization of in-vitro diagnostics. The firm invents innovative surface functionalization chemistries for identifying pathogens and biomarkers. Among its current projects, Gemina is advancing the POC Antigen COVID test, a rapid, point-of-care lateral flow assay strip specifically designed to detect active COVID-19 infections. The company maintains its headquarters in Vancouver, Canada.

Comparable companies

Gemina Laboratories Ltd. is most often compared with the following Healthcare names:

ACMSYCLCSHMTXFPPCBPRVCFQPTFFSRBCFSYGGFTELIFZHCLF
More research on GLABF
GLABF technical analysis GLABF TheEdge Score Compare against peers
Open full interactive analysis & DCF →